|
gptkbp:instance_of
|
gptkb:Company
|
|
gptkbp:acquisition
|
gptkb:Immunomedics
gptkb:Allergan's_aesthetics_portfolio
gptkb:Allergan
gptkb:Stemcentrx
gptkb:Alder_Bio_Pharmaceuticals
gptkb:Celerion
Alder Bio Pharmaceuticals from Abb Vie
Allergan from Abb Vie
Allergan's aesthetics portfolio from Abb Vie
Breztri from Abb Vie
Celerion from Abb Vie
Imbruvica from Abb Vie
Immunomedics from Abb Vie
Mavenclad from Abb Vie
Neuroscience assets from Abb Vie
Neuroscience assets from Allergan
Rinvoq from Abb Vie
Skyrizi from Abb Vie
Stemcentrx from Abb Vie
Vraylar from Abb Vie
Zinbryta from Abb Vie
|
|
gptkbp:ceo
|
gptkb:Richard_A._Gonzalez
|
|
gptkbp:clinical_trial
|
Phase 3 trials for Rinvoq
Phase 3 trials for Skyrizi
|
|
gptkbp:employees
|
approximately 50,000
|
|
gptkbp:founded
|
gptkb:2013
|
|
gptkbp:headquarters
|
gptkb:North_Chicago,_Illinois
|
|
https://www.w3.org/2000/01/rdf-schema#label
|
Abb Vie Inc.
|
|
gptkbp:industry
|
gptkb:drug
|
|
gptkbp:partnership
|
gptkb:healthcare_organization
gptkb:Duke_University
gptkb:Harvard_University
gptkb:University_of_California,_San_Francisco
gptkb:University_of_Chicago
|
|
gptkbp:products
|
gptkb:Humira
|
|
gptkbp:research_focus
|
oncology
neuroscience
immunology
virology
|
|
gptkbp:revenue
|
approximately $56 billion (2022)
|
|
gptkbp:symbol
|
gptkb:ABBV
|
|
gptkbp:bfsParent
|
gptkb:NYSE
|
|
gptkbp:bfsLayer
|
3
|